CAS: 80751-85-5 - 6-Chloro-2,3,4,5-tetrahydro-3-methyl-1-(3-methylphenyl)-1H-3-benzazepine-7,8-diol
Formula:C18H20ClNO2
InChI:InChI=1S/C18H20ClNO2/c1-11-4-3-5-12(8-11)15-10-20(2)7-6-13-14(15)9-16(21)18(22)17(13)19/h3-5,8-9,15,21-22H,6-7,10H2,1-2H3
InChI key:InChIKey=JXMYTVOBSFOHAF-UHFFFAOYSA-N
SMILES:ClC=1C(O)=C(O)C=C2C1CCN(C)CC2C=3C=CC=C(C3)C
- Synonyms:
- 1H-3-benzazepine-7,8-diol, 6-chloro-2,3,4,5-tetrahydro-3-methyl-1-(3-methylphenyl)-
- 6-Chloro-2,3,4,5-tetrahydro-3-methyl-1-(3-methylphenyl)-1H-3-benzazepine-7,8-diol
- 6-Chloro-7,8-dihydroxy-3-methyl-1-(3-methylphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine
- Skf 83959
- 6-Chloro-3-methyl-1-(3-methylphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol
Brand | Product data | Purity | Price range | Estimated delivery |
---|---|---|---|---|
SKF-83959 hydrobromide REF: 7W-GL2943CAS: 80751-85-5 | - - - | To inquire | Thu 09 Jan 25 | |
SKF83959 REF: TM-T60835CAS: 80751-85-5 | 98.45% | 52.00 €~741.00 € | Wed 26 Feb 25 | |
6-Chloro-7,8-dihydroxy-3-methyl-1-(3-methylphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine REF: 3D-FC173463CAS: 80751-85-5 | Min. 95% | - - - | Discontinued product |
SKF83959
CAS:80751-85-5
SKF83959: dopamine D1 partial agonist, Ki: D1(1.18 nM), D5(7.56 nM), D2(920 nM), D3(399 nM); improves …
Formula:
C18H20ClNO2
Purity:
98.45%
Color and Shape:
Liquid
Molecular weight:
317.81
Ref: TM-T60835
1mg | 52.00 € | ||
5mg | 102.00 € | ||
10mg | 166.00 € | ||
25mg | 353.00 € | ||
50mg | 522.00 € | ||
100mg | 741.00 € | ||
1mL*10mM (DMSO) | 113.00 € |
Estimated delivery in United States, on Wednesday 26 Feb 2025
6-Chloro-7,8-dihydroxy-3-methyl-1-(3-methylphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine
CAS:80751-85-5
6-Chloro-7,8-dihydroxy-3-methyl-1-(3-methylphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine (6C7DMHTB) is a drug metabolite that is produced by the cytochrome P450 enzyme. It …
Formula:
C18H20ClNO2
Purity:
Min. 95%
Molecular weight:
317.81 g/mol
Ref: 3D-FC173463
1mg | Discontinued | Request information | |
5mg | Discontinued | Request information | |
10mg | Discontinued | Request information |